Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald S Go

Showing results (201-210 of 402) with videos related to

Pageof 41
Sort By:
Blood Cancer Journal|June 28, 2022
Clinical and therapeutic implications of BRAF fusions in histiocytic disordersSaurabh Zanwar, Jithma P Abeykoon, Surendra Dasari, et al.
Leukemia & Lymphoma|July 25, 2022
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United StatesKaran L Chohan, Jithma P Abeykoon, Stephen M Ansell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 19, 2015
Institutional review of compliance with NCCN guidelines for breast cancer: lessons learned from real-time multidimensional synoptic reportingTitilayo O Adegboyega, Jeffrey Landercasper, Jared H Linebarger, et al.
Haematologica|May 25, 2019
Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i>Jérôme Razanamahery, Eli L Diamond, Fleur Cohen-Aubart, et al.
The Oncologist|May 31, 2022
Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experienceGaurav Goyal, Jason R Young, Jithma P Abeykoon, et al.
American Journal of Hematology|June 14, 2020
A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United StatesGordon J Ruan, Caleb J Smith, Courtney Day, et al.
American Journal of Hematology|July 28, 2015
Outcomes of primary refractory multiple myeloma and the impact of novel therapiesNeil Majithia, S Vincent Rajkumar, Martha Q Lacy, et al.
The Oncologist|September 28, 2020
Efficacy of BRAF-Inhibitor Therapy in BRAF<sup>V600E</sup> -Mutated Adult Langerhans Cell HistiocytosisAntonious Z Hazim, Gordon J Ruan, Aishwarya Ravindran, et al.
Mayo Clinic Proceedings|September 2, 2019
The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman DiseaseGaurav Goyal, Jason R Young, Matthew J Koster, et al.
American Journal of Hematology|July 7, 2015
Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myelomaMoritz Binder, S Vincent Rajkumar, Morie A Gertz, et al.
Pageof 41

Showing results (201-210 of 402) with videos related to

Sort By:
Pageof 41
Blood Cancer Journal|June 28, 2022
Clinical and therapeutic implications of BRAF fusions in histiocytic disordersSaurabh Zanwar, Jithma P Abeykoon, Surendra Dasari, et al.
Leukemia & Lymphoma|July 25, 2022
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United StatesKaran L Chohan, Jithma P Abeykoon, Stephen M Ansell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 19, 2015
Institutional review of compliance with NCCN guidelines for breast cancer: lessons learned from real-time multidimensional synoptic reportingTitilayo O Adegboyega, Jeffrey Landercasper, Jared H Linebarger, et al.
Haematologica|May 25, 2019
Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i>Jérôme Razanamahery, Eli L Diamond, Fleur Cohen-Aubart, et al.
The Oncologist|May 31, 2022
Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experienceGaurav Goyal, Jason R Young, Jithma P Abeykoon, et al.
American Journal of Hematology|June 14, 2020
A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United StatesGordon J Ruan, Caleb J Smith, Courtney Day, et al.
American Journal of Hematology|July 28, 2015
Outcomes of primary refractory multiple myeloma and the impact of novel therapiesNeil Majithia, S Vincent Rajkumar, Martha Q Lacy, et al.
The Oncologist|September 28, 2020
Efficacy of BRAF-Inhibitor Therapy in BRAF<sup>V600E</sup> -Mutated Adult Langerhans Cell HistiocytosisAntonious Z Hazim, Gordon J Ruan, Aishwarya Ravindran, et al.
Mayo Clinic Proceedings|September 2, 2019
The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman DiseaseGaurav Goyal, Jason R Young, Matthew J Koster, et al.
American Journal of Hematology|July 7, 2015
Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myelomaMoritz Binder, S Vincent Rajkumar, Morie A Gertz, et al.
Pageof 41